Biora Therapeutics, Inc. (BIOR)

Market Cap	22.07M
Revenue (ttm)	4,000
Net Income (ttm)	-124.12M
Shares Out	35.88M
EPS (ttm)	-7.87
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	103,390
Open	0.600
Previous Close	0.600
Day's Range	0.600 - 0.620
52-Week Range	0.585 - 6.700
Beta	1.09
Analysts	Strong Buy
Price Target	50.00 (+8,030.08%)
Earnings Date	May 13, 2024

About BIOR

Biora Therapeutics, Inc., a biotechnology company, engages in developing oral biotherapeutics. The company's targeted therapeutics program uses an ingestible smart capsule for targeted delivery of therapeutics in the gastrointestinal (GI) tract to enhance the treatment of inflammatory bowel diseases; and Systemic oral delivery platform for oral delivery of large molecules for management of chronic diseases. The company was formerly known as Progenity, Inc. and changed its name to Biora Therapeutics, Inc. in April 2022 to reflect its focus on it...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 19, 2020
• Employees: 58
• Stock Exchange: NASDAQ
• Ticker Symbol: BIOR

Financial Performance

In 2023, BIOR's revenue was $4,000, a decrease of -98.69% compared to the previous year's $305,000. Losses were -$124.12 million, 225.3% more than in 2022.

Analyst Forecast

According to one analyst, the rating for BIOR stock is "Strong Buy" and the 12-month stock price forecast is $50.0.

Price Target

$50.0

(8,030.08% upside)

Analyst Consensus: Strong Buy